Clinical trials: Chordomas
Solid Tumor Malignancies
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
This protocol will examine the safety of intratumoral administration of Clostridium Novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C.
- Trial name
- NCT01924689
- Testing
- Clostridium novyi-NT spores
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- BioMed Valley Discoveries, Inc
Skull Base Chordoma
Multi-parametric Imaging in Personalized Radiotherapy
The study consists in the retrospective and prospective collection of imaging data (along with clinical information related to treatment) of skull-base chordoma patients treated with particle therapy, to derive imaging biomarkers…
- Trial name
- NCT05888064
- Testing
- diffusion MRI sequences
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Synovial Sarcoma, Soft Tissue Sarcoma
A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors
This is an open-label, non-randomized, first-in-human Phase 1/2 study designed to evaluate the safety and tolerability of CFT8634 in subjects with synovial sarcoma and SMARCB1-null tumors who: have received prior systemic…
- Trial name
- NCT05355753
- Testing
- CFT8634
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- C4 Therapeutics, Inc.
Chordoma of Spine, Surgery
A Prospective Study of Surgical Treatment Strategies for Chordoma
Chordoma is a rare but locally invasive cancer that arises from the embryonic notochord. Total resection is challenging in mobile spine because of the complex anatomy and bone invasion.
- Trial name
- NCT05707767
- Testing
- Resection surgery
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xuanwu Hospital, Beijing
Chordoma
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
This is a multi-center study to assess the safety and to determine the maximum tolerated dose of the combination of imatinib and LBH589 in patients with newly diagnosed and recurrent chordoma.
- Trial name
- NCT01175109
- Testing
- Imatinib + LBH589
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Deric M Park MD
Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about…
- Conditions
- Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Childhood Epithelioid Sarcoma
- Trial name
- NCT01567046
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Children's Oncology Group
Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
The purpose of this study is to collect and store tumor tissue, blood, and bone marrow samples from patients with soft tissue sarcoma that will be tested in the laboratory.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Chordoma, Desmoid-Type Fibromatosis
- Trial name
- NCT00919269
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- 247 sites in United States, Australia and 5 more
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Chordoma
Efficacy and Safety of Imatinib in Chordoma
Preliminary response data, observed by Casali (Cancer, 2004) with imatinib 800 mg/day in patients affected by chordoma, need to be confirmed by a Phase II study, whose primary endpoint will be the formal assessment of clinical…
- Trial name
- NCT00150072
- Testing
- imatinib
- Where
- 12 sites in Italy, Switzerland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK)
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments.
- Conditions
- Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features
- Trial name
- NCT02601950
- Testing
- Tazemetostat
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 267 people
- Sponsor
- Epizyme, Inc.
Chordoma of Clivus
Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma
This is a single arm, open label, single center, and prospective, interventional study to explore clinical efficacy of afatinib in patients with chordoma of skull base.
- Trial name
- NCT05519917
- Testing
- Afatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huashan Hospital
Spinal Metastases, Vertebral Metastases
Stereotactic Body Radiotherapy for Spine Tumors
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.
- Conditions
- Spinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma
- Trial name
- NCT01347307
- Testing
- SBRT for Benign Extradural Spine Tumors, SBRT for Vertebral/Paraspinal Metastases
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mercy Research
Chordoma
Proton Beam Therapy for Chordoma Patients
The goal of this clinical research study is to learn if proton beam therapy, with or without photon beam radiation therapy, is effective in the treatment of skull base chordoma. The safety of this treatment will also be studied.
- Trial name
- NCT00496119
- Testing
- Proton Beam Therapy, Photon Beam Therapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors.
- Trial name
- FLAGSHP-1 (NCT04670679)
- Testing
- ERAS-601, Cetuximab, Pembrolizumab
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Erasca, Inc.
Chordoma of Spine, Chordoma of Skull Base
Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma
In this study the investigators will study the effects of neoadjuvant radiation therapy (RT), in the form of either proton therapy or stereotactic body radiation therapy (SBRT), on the Circulating tumor DNA (ctDNA), radiographic…
- Conditions
- Chordoma of Spine, Chordoma of Skull Base, Chordoma of Sacrum
- Trial name
- Canon (NCT06463262)
- Testing
- ctDNA
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer, Cystic Carcinomas, Adenoid
Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE
Since the 1990s, carbonetherapy radiotherapy has been developed in a few sites around the world, mainly to treat inoperable and highly radioresistant tumors.
- Conditions
- Cancer, Cystic Carcinomas, Adenoid, Soft-tissue Sarcomas, Rhabdomyosarcoma Pleomorphic
- Trial name
- PRIMHADRON (NCT06535997)
- Testing
- Questionnaire
- Where
- 2 sites in France
- Volunteers
- 62 people
- Sponsor
- Hospices Civils de Lyon
Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory…
- Conditions
- Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma, Small Cell Carcinoma of the Ovary Hypercalcemic Type
- Trial name
- NCT03874455
- Testing
- Tazemetostat
- Sponsor
- Epizyme, Inc.
Pituitary Tumor, Meningioma
Long-Term Longitudinal QoL in Patients Undergoing EEA
This is a prospective longitudinal study to access postoperative 2-year quality of life in patients who undergo endonasal endoscopic approach surgeries of the skull base.
- Conditions
- Pituitary Tumor, Meningioma, Rathke Cleft Cysts, Chordoma
- Trial name
- NCT04087902
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Ohio State University
Sacral Chordoma
Ion Irradiation of Sacrococcygeal Chordoma
The purpose of this study is to evaluate the safety and feasibility of primary hypofractionated irradiation of sacrococcygeal chordoma with carbon ions or protons using the raster scan technique.
- Trial name
- ISAC (NCT01811394)
- Testing
- protons, carbon ions
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Heidelberg University
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory).
- Conditions
- Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT05286801
- Testing
- Atezolizumab, Biospecimen Collection, Computed Tomography
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)